TuHURA Biosciences details Q2 cash burn and $50M facility

TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, reported second quarter 2026 results and a corporate update focused on advancing IFx-2.0, TBS-2025 and MDSC inhibitor ADC programs.

Rhea-AI Filing Summary

TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, reported second quarter 2026 results and a corporate update focused on advancing IFx-2.0, TBS-2025 and MDSC inhibitor ADC programs. The company highlighted multiple expected milestones through 2027, including prospective orphan drug designations and key trial initiations and readouts.

TuHURA reported cash and cash equivalents of $1.0 million as of June 30, 2026, and noted access to a recently announced $50 million term credit facility from its largest shareholder, described as non-convertible and expected to extend its cash runway into 2028. The facility bears 12% annual interest, with interest paid monthly and principal due at maturity on April 21, 2031, and can be drawn as needed to fund clinical and operating expenses.

For the quarter, research and development expenses were $6.6 million versus $4.9 million a year earlier, mainly from increased clinical activity, while general and administrative expenses were $2.1 million versus $1.9 million, driven in part by non-cash stock compensation and public company costs. Net cash outflows from operating activities were $13.0 million for the six months ended June 30, 2026, compared with $10.9 million in the prior-year period, partially offset by $10.6 million of net cash from financing activities. Common shares outstanding were approximately 63.7 million at June 30, 2026.

Positive

• $50 million non-convertible credit facility from the largest shareholder extends anticipated cash runway into 2028 and can be drawn as needed to support clinical development and operations.
• Pipeline progress with clearly defined 2026–2027 clinical and regulatory milestones, including planned Phase 1b/2 trial initiation for TBS-2025 and Phase 3 enrollment completion for IFx-2.0.

Negative

• Very low period-end cash and cash equivalents of $1.0 million alongside net operating cash outflows of $13.0 million for the first half of 2026 indicate heavy reliance on external funding.
• The new $50 million credit facility carries a 12% annual interest rate, adding a significant future interest burden on top of existing operating cash burn.

Filing Explained

The company received $5.7 million from Parkview and ATM proceeds of $0.3 million in April and $0.1 million in July; shares sold are undisclosed.

The filing reports that TuHURA Biosciences has completed part of this financing: it received $0.3 million under its ATM program in April 2026, $0.1 million in July 2026, and $5.7 million under the Parkview credit facility. Financing capital was therefore received, but the disclosure does not establish that the full $50 million facility was funded.

An ATM program lets the company sell new shares gradually at prevailing market prices. The filing reports the proceeds but gives no number of ATM shares sold, so the dilution from those sales cannot be sized from this disclosure.

The stated $50 million facility is not the amount received: the company reports $5.7 million in gross proceeds to date, including $2.15 million received after June 30, 2026. Under the loan agreement, outstanding funds bear 12% annual interest, paid monthly, with principal due on April 21, 2031.

The filing leaves the number of ATM shares sold and the facility amount still available undisclosed, limiting assessment of dilution and remaining financing capacity.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Cash and cash equivalents: $1.0 million Term credit facility size: $50 million Credit facility interest rate: 12% annual interest +5 more

8 metrics

Cash and cash equivalents $1.0 million As of June 30, 2026

Term credit facility size $50 million Non-convertible credit facility provided by largest shareholder

Credit facility interest rate 12% annual interest Interest on outstanding amounts under term credit facility

R&D expense Q2 2026 $6.6 million Three months ended June 30, 2026

R&D expense Q2 2025 $4.9 million Three months ended June 30, 2025

Net operating cash outflows $13.0 million Net cash outflows from operating activities, six months ended June 30, 2026

Net financing cash inflows $10.6 million Net cash flows from financing activities, six months ended June 30, 2026

Common shares outstanding 63.7 million Total common shares outstanding at June 30, 2026

Key Terms

orphan drug designation, Phase 3 registration trial, Investigational New Drug (IND) Application, at-the-market offering program, +2 more

6 terms

orphan drug designation regulatory

"Expect to receive orphan drug designation in MCC"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

Phase 3 registration trial medical

"randomized placebo-controlled Phase 3 registration trial of IFx-2.0"

A phase 3 registration trial is the large, late-stage clinical study designed to prove a drug or medical product is safe and effective enough for regulators to grant approval. Think of it as the final dress rehearsal before a product is allowed on the market: its results are the main evidence regulators review and are therefore a key driver of a potential product’s future sales, valuation, and investor risk or reward.

Investigational New Drug (IND) Application regulatory

"Filed Investigational New Drug (IND) Application for evaluation of the TBS-2025"

An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.

at-the-market offering program financial

"received $0.3 million and $0.1 million, respectively, in gross proceeds under the ATM Program"

An at-the-market offering program lets a company sell newly issued shares directly into the open market at current trading prices through a broker, rather than issuing a large block of stock all at once. It matters to investors because it provides the company a flexible way to raise cash over time, which can dilute existing shares gradually and affect earnings per share and stock price depending on how much and when shares are sold—think of it as a faucet the company can open or close to add supply to the market.

antibody drug conjugates (ADCs) medical

"bi-specific, bi-functional antibody drug conjugates (ADCs) targeting MDSCs"

Antibody drug conjugates (ADCs) are specialized medicines that combine a targeted antibody with a powerful drug, designed to attack specific disease cells while minimizing harm to healthy ones. This approach allows for more precise treatment, often leading to better outcomes. For investors, ADCs represent innovative therapies with the potential for significant market impact and growth in the healthcare sector.

term credit facility financial

"recent $50 million term credit facility made available to us"

Earnings Snapshot

R&D expenses Q2 2026: $6.6 million

three and six months ended June 30, 2026

R&D expenses Q2 2026 $6.6 million $1.7 million increase versus Q2 2025

G&A expenses Q2 2026 $2.1 million $0.3 million increase versus Q2 2025

Net operating cash outflows H1 2026 $13.0 million $2.1 million higher than H1 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were TuHURA Biosciences (HURA) cash and liquidity levels at June 30, 2026?

TuHURA reported cash and cash equivalents of $1.0 million as of June 30, 2026. Liquidity is supplemented by a $50 million term credit facility from its largest shareholder and proceeds from an at-the-market offering and the Parkview credit facility.

How large is TuHURA Biosciences’ new credit facility and what are its terms?

TuHURA has a $50 million term credit facility from its largest shareholder, bearing 12% annual interest on drawn amounts. Interest is paid monthly, with principal due at a five-year maturity on April 21, 2031, and funds can be drawn as needed.

What were TuHURA Biosciences (HURA) R&D and G&A expenses in Q2 2026?

For the three months ended June 30, 2026, R&D expenses were $6.6 million, up from $4.9 million in 2025, reflecting increased clinical activity. G&A expenses were $2.1 million, compared with $1.9 million a year earlier, mainly from stock compensation and public company costs.

How much cash did TuHURA Biosciences (HURA) use in operations in the first half of 2026?

Net cash outflows from operating activities were $13.0 million for the six months ended June 30, 2026, compared with $10.9 million in the prior-year period. Net cash from financing activities totaled $10.6 million over the same 2026 period.

What are the key upcoming clinical milestones for TuHURA Biosciences programs?

Planned milestones include Phase 1b/2 trial initiation for TBS-2025 in mutNPM1 r/r AML in 2H 2026, expected orphan drug designations for IFx-2.0 in MCC and TBS-2025 in AML, and completion of IFx-2.0 Phase 3 enrollment in 2H 2027.

How many TuHURA Biosciences (HURA) common shares were outstanding at June 30, 2026?

TuHURA reported approximately 63.7 million common shares outstanding as of June 30, 2026. This figure provides context for assessing the scale of financing activities and potential future dilution from additional capital raises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 07:50 AM Accepted by SEC EDGAR 08/14/2026 - 07:50 AM Learn about SEC filing dates

false0001498382TuHURA Biosciences, Inc./NV00014983822026-08-142026-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2026

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Nevada		001-37823		99-0360497
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
10500 University Center Dr., Suite 110
Tampa, Florida 33612
(Address of Principal Executive Offices, including zip code)
Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		HURA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2026, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2026, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No. Document

99.1 Press Release, dated August 14, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TUHURA BIOSCIENCES, INC.
Date:	August 14, 2026	By:	/s/ Dan Dearborn
			Name: Dan Dearborn Title: Chief Financial Officer

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TAMPA, Fla., August 14, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.

“We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year,” said Dr. James Bianco, President and CEO of TuHURA Biosciences. “In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating our Phase 1b/2 trial of VISTA in mutNPM1 r/r AML, initiating our in vivo POC studies for MDSC Inhibitors (Bi-specific antibody drug conjugates (ADCs)), potentially receiving orphan drug designation in Merkel cell carcinoma (MCC) for IFx-2.0, and potentially receiving orphan drug designation in AML for TBS-2025. The recent $50 million term credit facility made available to us by our largest shareholder provides us a non-convertible source of operating capital with adequate runway for us to achieve our strategic objectives and execute on our goals.”

Second Quarter and Recent Corporate Highlights:

•Filed Investigational New Drug (IND) Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and other Blood Related Cancers. The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML). The FDA noted that the previously planned IND meeting would not be necessary and instead the FDA provided written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML.

•In April 2026, the Company announced a $50 million credit facility and royalty transaction extending its anticipated cash runway into 2028. Under the terms of the loan agreement for the credit facility, TuHURA will have the ability to draw down on the facility on an as-needed basis to fund monthly expenses for ongoing clinical development and operations. The facility bears a 12% annual interest rate on outstanding funds drawn, with interest paid monthly and principal repayment due

at a 5-year maturity date for April 21, 2031. The facility was provided by TuHURA’s largest shareholder.

Currently Anticipated Milestones by Program

IFx-2.0 (Innate Immune Agonist)

•2H 2026: Expect to receive orphan drug designation in MCC

•1H2027: Expect preliminary results from IR study IFX-2.0 with Keytruda® for deep seated MCC

•2H 2027: Expect to complete enrollment in the Phase 3 study of IFx-2.0

TBS-2025 (VISTA inhibiting mAb)

•2H 2026: Expect to initiate Phase 1b/2 trial of VISTA in mutNPM1 r/r AML

•2H 2026: Expect to receive orphan drug designation in AML

•1H 2027: Expect preliminary safety and response data for VISTA in mutated NMP1 r/r AML

MDSC Inhibitors (Bi-specific ADCs)

•2H 2026: Presentations at key scientific meetings

•2H 2026: Initiation of ADC in vivo POC studies

Summary of Financial Results for the Second Quarter 2026

Cash and cash equivalents of $1.0 million at June 30, 2026. In April 2026 and July 2026, the Company received $0.3 million and $0.1 million, respectively, in gross proceeds under the ATM Program. Additionally, the Company has received $5.7 million in gross proceeds to date on the Parkview credit facility, which includes $2.15 million subsequent to June 30, 2026. TuHURA's total common shares outstanding were approximately 63.7 million at June 30, 2026.

Research and development expenses were $6.6 million and $4.9 million for the 3 months ended June 30, 2026, and 2025, respectively. The increase of $1.7 million was related to an increase in clinical development activity the Company’s ongoing and planned clinical trials.

General and administrative (G&A) expenses were $2.1 million and $1.9 million for the 3 months ended June 30, 2026, and 2025, respectively. The increase of $0.3 million was primarily due to increases in non-cash stock compensation expense and costs associated with being a public company.

Net cash outflows from operating activities were ($13.0) million and ($10.9) million for the 6 months ended June 30, 2026, and 2025, respectively.

Net cash flows from financing activities were $10.6 million and $8.1 million for the 6 months ended June 30, 2026, and 2025, respectively.

About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is enrolling patients in its randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, a VISTA inhibiting mAb moving into dose escalation/optimization Phase 1b trial in mutNPM1 r/r AML, a molecularly defined subgroup representing approximately 35% of patients with AML. TuHURA is also leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting MDSCs to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-Looking Statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words

such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely,” or the negative or plural of these words or similar expressions. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others: the risk that funds available under the Company’s credit facility may be insufficient to fund the Company’s operations and development programs to the extent anticipated; risks associated with conducting the ongoing Phase 3 trial for IFx.20; the risks associated with continuing the development of TBS-2025 and our DOR technologies; risks related to patient enrollment, trial design, data outcomes and regulatory interactions; uncertainty regarding the timing and likelihood of regulatory approvals; and the other risks described from time to time in detail in Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and TuHURA’s other reports and filings with the SEC from time to time, which are available on TuHURA’s website and at www.sec.gov.

The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Investor Contact:

Monique Kosse

Gilmartin Group

Monique@GilmartinIR.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 35.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 30.1 KB